24 Citations (Scopus)

Abstract

Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

Original languageEnglish (US)
Pages (from-to)387-389
Number of pages3
JournalCell Metabolism
Volume20
Issue number3
DOIs
StatePublished - Sep 2 2014

Fingerprint

Random Allocation
Coronary Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Triglycerides
Mutation
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Cite this

APOC3, coronary disease, and complexities of mendelian randomization. / Cohen, Jonathan C.; Stender, Stefan; Hobbs, Helen H.

In: Cell Metabolism, Vol. 20, No. 3, 02.09.2014, p. 387-389.

Research output: Contribution to journalArticle

@article{7b8e6f8805eb4fbe93135f0414cba593,
title = "APOC3, coronary disease, and complexities of mendelian randomization",
abstract = "Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; J{\o}rgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.",
author = "Cohen, {Jonathan C.} and Stefan Stender and Hobbs, {Helen H.}",
year = "2014",
month = "9",
day = "2",
doi = "10.1016/j.cmet.2014.08.007",
language = "English (US)",
volume = "20",
pages = "387--389",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - APOC3, coronary disease, and complexities of mendelian randomization

AU - Cohen, Jonathan C.

AU - Stender, Stefan

AU - Hobbs, Helen H.

PY - 2014/9/2

Y1 - 2014/9/2

N2 - Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

AB - Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

UR - http://www.scopus.com/inward/record.url?scp=84913596368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913596368&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2014.08.007

DO - 10.1016/j.cmet.2014.08.007

M3 - Article

VL - 20

SP - 387

EP - 389

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 3

ER -